Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USA
Abigail L. Carlson
, Daniel M. Pastula, Amy J. Lambert, J. Erin Staples, Atis Muehlenbachs, George Turabelidze, Charles S. Eby, Jesse Keller, Brian Hess, Richard S. Buller, Gregory A. Storch, Kathleen Byrnes, Louis Dehner, Nigar Kirmani, and F. Matthew Kuhlmann
Author affiliations: Veterans Affairs St. Louis Health Care System, St. Louis, Missouri, USA (A.L. Carlson); Washington University School of Medicine, St. Louis (A.L. Carlson, C.S. Eby, J. Keller, B. Hess, R.S. Buller, G.A. Storch, K. Byrnes, L. Dehner, N. Kirmani, F.M. Kuhlmann); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (D.M. Pastula, A.J. Lambert, J.E. Staples); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.M. Pastula, A. Muehlenbachs); Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA (G. Turabelidze)
Figure 1. Chronology of selected laboratory findings and therapeutic interventions for immunocompromised patient infected with Heartland virus, Missouri, USA. Gray bars indicate treatments administered. CVVHD, continuous veno-venous hemodialysis; IV, intravenous.
Page created: April 17, 2018
Page updated: April 17, 2018
Page reviewed: April 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.